학술논문

Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants.
Document Type
Article
Source
Molecular Neurodegeneration. 11/28/2023, Vol. 18 Issue 1, p1-4. 4p.
Subject
*DISEASE risk factors
*ALZHEIMER'S disease
*APOLIPOPROTEIN E
*APOLIPOPROTEIN E4
*MAJOR adverse cardiovascular events
*APOLIPOPROTEIN B
Language
ISSN
1750-1326
Abstract
This document explores the APOE gene and its connection to neurodegeneration and cardiovascular disease. Specifically, it focuses on the rare APOECh variant, which may offer protection against Alzheimer's disease. The study identified 37 individuals with this variant in the UK Biobank population and examined various traits and biomarkers associated with neurological and cardiovascular disorders. The findings suggest that APOECh carriers may have lower levels of apolipoprotein B, potentially providing protection against Alzheimer's disease and major adverse cardiovascular events. However, further research is needed to confirm these findings. The document also provides summary statistics on lipid biomarkers among APOECh carriers and noncarriers, highlighting the relationship between elevated apolipoprotein B levels and increased risk of Alzheimer's disease. The study acknowledges limitations, such as the small sample size, and emphasizes the need for larger cohorts to validate the findings. Overall, the document offers valuable insights into the role of APOECh in disease etiology, but more research is necessary to fully understand its impact on dementia, dyslipidemia, and cardiovascular disease. [Extracted from the article]